Liquid Biopsy Market Report: ctDNA Sequencing Service Market Size, Early Cancer Detection, and Personalized Therapy 2026-2032

Global Leading Market Research Publisher QYResearch announces the release of its latest report “ctDNA Sequencing Service – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global ctDNA Sequencing Service market, including market size, share, demand, industry development status, and forecasts for the next few years.

Oncologists and clinical researchers have long faced a fundamental challenge in cancer management: tumor heterogeneity and the inability to perform repeated tissue biopsies without risking patient harm. Traditional tissue biopsies capture only a single snapshot of a tumor, missing emerging resistance mutations and metastatic subclones. The solution lies in liquid biopsy technology. The global ctDNA Sequencing Service market size was valued at approximately USD 956 million in 2025 and is projected to reach USD 1,506 million by 2032, growing at a CAGR of 6.8% from 2026 to 2032. This growth is driven by the expanding clinical utility of circulating tumor DNA analysis in early cancer detection, treatment monitoring, and minimal residual disease (MRD) assessment.

ctDNA Sequencing Service is a high-sensitivity molecular testing technique based on liquid biopsy, designed to detect circulating tumor DNA (ctDNA) in body fluids such as blood plasma. ctDNA consists of short DNA fragments released by apoptotic or necrotic tumor cells, reflecting real-time tumor genetic alterations and evolution. This service involves cfDNA extraction from plasma, library preparation, targeted panel capture or whole-exome/genome sequencing, followed by advanced bioinformatics analysis to identify tumor-specific mutations, copy number variations, gene fusions, and methylation patterns. ctDNA sequencing is widely used in cancer early detection, drug selection, treatment monitoring, relapse prediction, and minimal residual disease assessment, making it a cornerstone of precision oncology and personalized cancer therapy.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6083879/ctdna-sequencing-service

Market Share Analysis: Competitive Landscape and Service Differentiation

The ctDNA Sequencing Service market share analysis reveals a diversified competitive landscape comprising specialized CROs (CD Genomics, OncoDNA, TATAA Biocenter, Signios Bio, Abnova, Frontage, Creative Biolabs, SEQanswers), sequencing platform leaders (Illumina, PacBio), and clinical integrated diagnostics providers (Tempus). Unlike the consolidated NGS instrument market, the ctDNA sequencing service segment remains fragmented, with no single player exceeding 15% global share as of Q1 2026. Tempus has gained traction through its partnerships with over 65% of U.S. NCI-designated cancer centers, while OncoDNA maintains leadership in European oncology networks. Illumina, despite its platform dominance, primarily sells instruments rather than direct clinical sequencing services, positioning PacBio as a notable challenger for long-read ctDNA applications enabling structural variant detection.

Recent Industry Data (December 2025):
The Centers for Medicare & Medicaid Services (CMS) expanded coverage for ctDNA-based MRD testing in colorectal cancer, effective January 2026. This reimbursement decision is projected to increase annual test volumes by approximately 180,000 in the U.S. alone, directly expanding the liquid biopsy serviceable market by an estimated USD 210 million over 2026–2027.

Segmentation Analysis: Technology Types and Clinical Applications

The ctDNA Sequencing Service market is segmented as below:

By Company
CD Genomics, OncoDNA, TATAA Biocenter, Signios Bio, Abnova, Frontage, Illumina, Creative Biolabs, SEQanswers, Tempus, PacBio

Segment by Type

• ctDNA Whole-Genome Resequencing (WGS) : Comprehensive but cost-intensive (USD 1,500–2,500 per sample), typically reserved for research and discovery settings.
• ctDNA Exome Sequencing : Focuses on protein-coding regions; balances depth and breadth for mutation discovery.
• ctDNA Methylation Sequencing : Increasingly used for early cancer detection, as methylation patterns often precede genetic mutations. A 2025 multi-cancer early detection study demonstrated 88% sensitivity across 12 tumor types using methylation-only approaches.
• ctDNA Targeted Region Sequencing : Dominates clinical applications due to lower cost (USD 300–800 per sample), higher depth (50,000–100,000x coverage), and faster turnaround (5–10 days). Most commercial MRD tests fall into this category.

Segment by Application

• Detection of Early-Stage Cancer : Screening asymptomatic populations; largest growth segment with projected CAGR of 11.2% through 2032.
• Recurrence Prediction : Post-surgical and post-treatment MRD monitoring; second-largest segment.
• Personalized Therapy : Companion diagnostics for targeted therapies and immunotherapies.
• Others : Clinical trial enrollment screening, pharmacodynamic monitoring in drug development.

Industry Depth: Clinical Workflow Disparities Across Care Settings

A distinctive precision oncology perspective emerges when comparing ctDNA sequencing adoption across community oncology practices versus academic medical centers. Community practices (accounting for approximately 75% of U.S. cancer care delivery) typically outsource ctDNA sequencing to reference laboratories, prioritizing circulating tumor DNA analysis results with interpretable reports and reimbursement support. Turnaround time expectations range from 7–10 days. In contrast, academic medical centers increasingly perform in-house ctDNA sequencing for research-integrated care, enabling real-time tracking of clonal evolution and resistance mechanisms, often with 3–5 day turnaround using automated platforms like Illumina’s NovaSeq X. This workflow divergence directly impacts service provider strategies: companies like Tempus and CD Genomics offer hybrid models supporting both outsourced community testing and academic research collaborations.

Technical Challenges and Mitigation Strategies

Despite clinical promise, three technical challenges limit broader ctDNA sequencing adoption. First, low variant allele frequency (VAF) detection—early-stage tumors shed as little as 0.01–0.1% mutant cfDNA fragments among abundant wild-type cfDNA—requires ultra-deep sequencing (50,000–100,000x) and error-correction molecular barcoding. Second, clonal hematopoiesis of indeterminate potential (CHIP) can produce false-positive mutation calls when age-related hematopoietic mutations are misattributed to tumor origin. Third, pre-analytical variability in blood collection tubes, plasma separation timing, and cfDNA extraction efficiency affects inter-lab reproducibility.

Typical User Case (Q1 2026):
A multicenter European consortium evaluating ctDNA-guided adjuvant therapy in stage II colon cancer reported that patients with post-surgical ctDNA positivity had a 78% recurrence rate at 24 months compared to 8% in ctDNA-negative patients. Based on these findings, six participating hospitals modified clinical protocols to escalate therapy in ctDNA-positive patients, demonstrating direct treatment impact. However, the consortium noted that inter-lab concordance for low-VAF calls (below 0.05%) remained only 72%, highlighting the need for standardized reference materials.

Strategic Outlook and Recommendations

As precision oncology advances, the ctDNA Sequencing Service market size will increasingly shift from research-driven to clinical routine applications. By 2028, experts anticipate that ctDNA-based MRD testing will become standard of care for at least eight solid tumor types, following the colorectal cancer precedent. For service providers and diagnostic laboratories, differentiation will depend on three factors: (1) demonstrating clinical utility through prospective trial evidence, (2) achieving regulatory approvals (FDA, CE-IVDR) for specific use cases, and (3) building integrated reporting systems that directly connect ctDNA findings to therapy selection. The companies best positioned for market share growth are those investing in automated, high-throughput workflows capable of delivering 5-day turnaround at sub-USD 500 pricing.

Contact Us
If you have any queries regarding this report or if you would like further information, please contact us:

QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp